LEXINGTON, Ky. (LEX 18) — A COVID-19 vaccine being tested at the University of Kentucky showed promising results in its preclinical trials.
PDS Biotechnology, a clinical-stage immunotherapy company, recently released its findings for the vaccine candidate PDS0203, which is being tested at UK’s College of Medicine.
The vaccine is unique to others currently in development because it uses a technology pioneered by PDS Biotech called Versamune, which activates the T cells critical to the body’s immune system response.
When tested in mice, the vaccine showed a strong response in protective antibodies, as well as virus-specific “killer” and “helper” T cells within 14 days of testing.
PDS will now submit the findings to a peer-reviewed scientific journal and will then advance the vaccine to phase 1 clinical trials in humans.